Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance-Reference-Cited by-同舟云学术

Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance

Published:2023-11-28 Issue:1 Volume:38 Page:
ISSN:1095-6670
Container-title:Journal of Biochemical and Molecular Toxicology
language:en
Short-container-title:J Biochem & Molecular Tox

Author:

Cao Yaquan¹^ORCID,Wu Chunli²,Ma Liying³⁴

Affiliation:

1. College of Basic Medicine and Forensic Medicine Henan University of Science and Technology Luoyang China

2. School of Pharmaceutical Sciences Zhengzhou University Zhengzhou China

3. State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China

4. Key Laboratory of Cardio‐Cerebrovascular Drug China Meheco Topfond Pharmaceutical Company Zhumadian China

Abstract

AbstractChemoresistance, a roadblock in the chemotherapy process, has been impeding its effective treatment. KDM5B, a member of the histone demethylase family, has been crucial in the emergence and growth of malignancies. More significantly, KDM5B has recently been linked closely to cancer's resistance to chemotherapy. In this review, we explain the biological properties of KDM5B, its function in the emergence and evolution of cancer treatment resistance, and our hopes for future drug resistance‐busting combinations involving KDM5B and related targets or medications.

Publisher

Wiley

Subject

Health, Toxicology and Mutagenesis,Toxicology,Molecular Biology,Molecular Medicine,Biochemistry,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbt.23587

Reference138 articles.

1. Precision medicine: Ray of hope in overcoming cancer multidrug resistance

2. Molecular mechanisms of chemoresistance in gastric cancer

3. The molecular mechanisms of chemoresistance in cancers

4. Molecular mechanisms of breast cancer chemoresistance by immune checkpoints

5. Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer